Our Pricing

Mounjaro 10mg: UK Pricing, Dosing & Clinical Evidence

Finding mounjaro 10mg lowest price uk options requires comparing UK-registered pharmacies that offer transparent pricing and genuine licensed medication. At Cured Pharmacy, Mounjaro 10mg pens start from £135.00, with prices confirmed upfront before your free clinical consultation with a UK prescriber. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures every pen is UK-licensed, stored correctly, and dispensed only after appropriate clinical assessment.

Understanding Mounjaro 10mg: Clinical Mechanism & Evidence

Mounjaro 10mg represents the mid-range maintenance dose of tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway medications, tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously, producing enhanced effects on appetite regulation, gastric emptying, and metabolic function.

In the SURPASS-2 trial comparing tirzepatide directly against semaglutide 1mg, participants receiving tirzepatide 10mg achieved mean weight reductions of 12.4kg over 40 weeks, compared to 6.2kg with semaglutide [1][2]. The 10mg dose sits between the 5mg starter dose and the maximum 15mg dose, offering substantial efficacy whilst allowing prescribers to assess individual tolerance.

Clinical data demonstrates that approximately 89% of patients reaching the 10mg maintenance dose achieve at least 5% body weight reduction, with 55% achieving 15% or greater reduction over 72 weeks [1]. These outcomes position Mounjaro 10mg as one of the most effective pharmacological weight management options currently available through UK pharmacies.

Mounjaro 10mg Dosing Schedule & Titration Protocol

UK prescribers follow a structured dose escalation protocol when initiating Mounjaro treatment. Patients typically begin with 2.5mg weekly for four weeks, then increase to 5mg weekly for the next four weeks. The 10mg dose is introduced at week nine, provided the patient tolerates the 5mg dose without significant gastrointestinal effects [3].

This gradual titration reduces the incidence of nausea, vomiting, and diarrhoea—the most commonly reported side effects during initiation. In clinical trials, patients who followed the recommended escalation schedule experienced significantly fewer treatment discontinuations compared to those attempting faster dose increases [3].

Each Mounjaro 10mg KwikPen contains four weekly doses, administered subcutaneously in the abdomen, thigh, or upper arm. The pen design allows for simple self-administration without requiring manual dose adjustment, as each click delivers precisely 10mg of tirzepatide. Patients remain on the 10mg maintenance dose unless their prescriber determines that escalation to 15mg would provide additional clinical benefit.

When Prescribers Recommend the 10mg Dose

UK clinicians typically maintain patients at Mounjaro 10mg when they achieve consistent weight loss of 1-2% body weight per month and tolerate the medication well. If weight loss plateaus after eight weeks at 10mg, and the patient experiences no limiting side effects, prescribers may consider increasing to the maximum 15mg dose. Conversely, patients experiencing persistent nausea or gastrointestinal discomfort at 10mg may benefit from remaining at 5mg for an extended period before re-attempting escalation.

Comparing Mounjaro 10mg Lowest Price UK Options

UK pricing for Mounjaro 10mg varies considerably between pharmacies, with monthly costs influenced by supply chain relationships, dispensing fees, and consultation models. At Cured Pharmacy, transparent upfront pricing means patients see the £135.00 cost before completing their clinical assessment—no hidden fees or post-consultation price increases.

When comparing options, consider the total service package rather than price alone. Cured Pharmacy includes free clinical consultation with UK-registered prescribers, discreet packaging as standard, and dispensing by our GPhC-registered pharmacy team. All Mounjaro pens are sourced directly from UK-licensed wholesalers and stored in temperature-controlled facilities to maintain medication integrity.

Some patients initially seek Mounjaro 10mg specifically, but UK prescribing protocols require starting at the 2.5mg dose regardless of previous treatment history. Your prescriber will determine when escalation to 10mg is clinically appropriate based on your response and tolerance. This regulatory requirement ensures patient safety and optimal therapeutic outcomes.

Mounjaro 10mg vs Alternative Weight Loss Treatments

UK patients often compare Mounjaro 10mg against other GLP-1 receptor agonists like Wegovy and Saxenda. Wegovy contains semaglutide, a single GLP-1 agonist, whilst Saxenda uses liraglutide, which requires daily rather than weekly injection. Head-to-head trials demonstrate tirzepatide's superior weight loss outcomes at equivalent treatment durations [2].

In the SURPASS-2 study, tirzepatide 10mg produced 7.6kg greater weight reduction than semaglutide 1mg over 40 weeks in patients with type 2 diabetes [2]. Whilst direct comparisons in weight management populations are ongoing, the dual-receptor mechanism provides theoretical advantages in appetite suppression and metabolic regulation.

Oral treatments like Orlistat work through entirely different mechanisms—blocking dietary fat absorption rather than affecting appetite hormones. Orlistat typically produces 3-5% body weight reduction, substantially less than injectable GLP-1 treatments, but may suit patients who prefer tablet formulations or have contraindications to injectable medications [4].

Choosing Between Injectable Options

Your UK prescriber will assess which treatment aligns with your medical history, weight loss goals, and lifestyle preferences. Factors influencing this decision include previous medication responses, injection frequency preference (weekly versus daily), and specific health conditions. Mounjaro 10mg may be particularly suitable for patients who have not achieved adequate results with single-pathway GLP-1 treatments or who prefer the convenience of once-weekly administration with a pre-filled, fixed-dose pen.

Side Effects & Safety Considerations at 10mg Dose

The most frequently reported side effects of Mounjaro 10mg are gastrointestinal: nausea affects approximately 25-30% of patients at this dose, whilst diarrhoea, vomiting, and constipation each occur in 15-20% of users [1][3]. These effects typically emerge within the first few weeks after dose escalation and diminish over subsequent weeks as the body adapts.

More serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia (particularly in patients taking concurrent diabetes medications). UK prescribers conduct thorough medical history assessments to identify patients at elevated risk for these complications. Mounjaro is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [3].

Clinical trial data shows that treatment discontinuation rates due to adverse events remain relatively low at the 10mg dose—approximately 6-8% of participants in the SURMOUNT-1 trial discontinued specifically due to gastrointestinal side effects [1]. This suggests the 10mg dose strikes a balance between efficacy and tolerability for most patients who have successfully titrated from lower doses.

Managing Common Side Effects

UK pharmacists typically advise patients to eat smaller, more frequent meals, avoid high-fat foods, and stay well-hydrated to minimise gastrointestinal symptoms. Injecting Mounjaro on the same day each week, preferably when you can rest if nausea occurs, helps establish a manageable routine. If side effects persist beyond four weeks at the 10mg dose or significantly impact daily functioning, contact your prescriber to discuss whether temporarily returning to 5mg would be appropriate.

Accessing Mounjaro 10mg Through UK Online Pharmacies

All UK pharmacies, whether online or high-street, must follow identical prescribing regulations for Mounjaro. The medication is prescription-only, requiring clinical assessment by a UK-registered prescriber before dispensing. At Cured Pharmacy, this assessment takes under three minutes via our online consultation platform, reviewed by GMC-registered doctors or independent prescribers.

Our consultation captures essential medical information including current medications, cardiovascular history, previous weight loss attempts, and contraindications specific to GLP-1 treatments. UK prescribers cannot issue Mounjaro prescriptions to patients with BMI below 30 kg/m² (or 27 kg/m² with weight-related comorbidities), in line with MHRA licensing and NICE guidance [5].

Once approved, Cured Pharmacy dispenses Mounjaro 10mg pens from our GPhC-registered premises (registration 9012511) via discreet courier service. Pens arrive in temperature-controlled packaging with clear storage instructions—Mounjaro must be refrigerated at 2-8°C until first use, then may be kept at room temperature (up to 30°C) for up to 21 days. Our pharmacy team provides written guidance with every order to ensure proper medication handling and injection technique.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Electronic Medicines Compendium. (2023). Mounjaro 10 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14395
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155
5. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating overweight and obesity. NICE technology appraisal guidance [TA1026]. https://www.nice.org.uk/guidance/ta1026

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, diet, and physical activity.